Graeme Duncan, CEO
Adeel Ahmad, CFO
With an agile and experienced team, including direct sales, marketing and medical capability across many of Europe’s major markets, ADVANZ PHARMA supplies, innovates and enhances the critical medicines patients depend on, ensuring continued patient access and improving healthcare outcomes.
ADVANZ PHARMA has a broad expertise in several therapeutic areas with particular strengths in the critical care, anti-infectives, endocrinology, cardiovascular and central nervous system therapeutic areas, along with direct sales access in Europe, making it an attractive partner when commercialising complex medicines.
ADVANZ PHARMA has commercial affiliates in Europe, North America and Australia, and supply chain, regulatory as well as administrative operations in India. Furthermore, ADVANZ PHARMA has an established global network of commercial partners throughout the rest of the world.
Nordic Capital acquired ADVANZ PHARMA in 2021. The investment is at the core of Nordic Capital’s healthcare investment strategy. As an active and supportive owner, Nordic Capital sees strong opportunities to further invest in and strengthen ADVANZ PHARMA’s platform and to accelerate the company’s pipeline of innovative specialty pharmaceutical products.
EUR 470 million
Nordic Capital Fund X (controlling shareholding)
London, United Kingdom